These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25947283)

  • 1. Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
    Kuroda J; Kobayashi T; Taniwaki M
    Expert Rev Anticancer Ther; 2015; 15(7):787-804. PubMed ID: 25947283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
    Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
    Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
    Usnarska-Zubkiewicz L; Dębski J; Butrym A; Legieć W; Hus M; Dmoszyńska A; Stella-Hołowiecka B; Zaucha JM; Januszczyk J; Rymko M; Torosian T; Charliński G; Lech-Marańda E; Malenda A; Jurczyszyn A; Urbańska-Ryś H; Druzd-Sitek A; Błońska D; Urbanowicz A; Hołojda J; Pogrzeba J; Rzepecki P; Hałka J; Subocz E; Becht R; Zdziarska B; Dytfeld D; Nowicki A; Bołkun Ł; Kłoczko J; Knopińska-Posłuszny W; Zubkiewicz-Kucharska A; Kuliczkowski K
    Leuk Res; 2016 Jan; 40():90-9. PubMed ID: 26626207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.
    Dimopoulos MA; Palumbo A; Attal M; Beksaç M; Davies FE; Delforge M; Einsele H; Hajek R; Harousseau JL; da Costa FL; Ludwig H; Mellqvist UH; Morgan GJ; San-Miguel JF; Zweegman S; Sonneveld P;
    Leukemia; 2011 May; 25(5):749-60. PubMed ID: 21293488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F; Baz R
    Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
    Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
    Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma.
    Nguyen-Pham TN; Jung SH; Vo MC; Thanh-Tran HT; Lee YK; Lee HJ; Choi NR; Hoang MD; Kim HJ; Lee JJ
    J Immunother; 2015 Oct; 38(8):330-9. PubMed ID: 26325377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
    Montefusco V; Galli M; Spina F; Stefanoni P; Mussetti A; Perrone G; De Philippis C; Dalto S; Maura F; Bonini C; Rezzonico F; Pennisi M; Roncari L; Soldarini M; Dodero A; Farina L; Cocito F; Caprioli C; Corradini P
    Leuk Lymphoma; 2014 Sep; 55(9):2032-7. PubMed ID: 24730540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel lenalidomide-based combinations for treatment of multiple myeloma.
    Cives M; Simone V; Brunetti O; Longo V; Silvestris F
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):9-20. PubMed ID: 22809697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How lenalidomide is changing the treatment of patients with multiple myeloma.
    Dimopoulos MA; Terpos E; Niesvizky R
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
    Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
    Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutral tumor evolution in myeloma is associated with poor prognosis.
    Johnson DC; Lenive O; Mitchell J; Jackson G; Owen R; Drayson M; Cook G; Jones JR; Pawlyn C; Davies FE; Walker BA; Wardell C; Gregory WM; Cairns D; Morgan GJ; Houlston RS; Kaiser MF
    Blood; 2017 Oct; 130(14):1639-1643. PubMed ID: 28827410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide: an update on evidence from clinical trials.
    Dimopoulos MA; Terpos E
    Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
    Anderson KC; Prince HM
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
    [No Abstract]   [Full Text] [Related]  

  • 19. An update on the use of lenalidomide for the treatment of multiple myeloma.
    Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2015; 16(12):1865-77. PubMed ID: 26165832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.